NCT06868537 A Trial of the Launching! to Adulthood Program
| NCT ID | NCT06868537 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center, Houston |
| Condition | Autism Spectrum Disorder (ASD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-07-15 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-07-15 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the effectiveness of the Launching intervention (Pagan et al., 2024) in improving adaptive functioning, transition readiness, and social cognition in young adults with Autism Spectrum Disorder (ASD), compared to a delayed treatment control group, to examine whether the Launching intervention leads to improvements in executive functioning, co-occurring mental health symptoms, and quality of life, as measured by caregiver and self-report assessments, to assess the maintenance of treatment gains 12 weeks post-treatment and to replicate the findings of the Launching pilot study in an independent sample of young adults with ASD.
Eligibility Criteria
Inclusion Criteria: * confirmed case of ASD from a licensed mental health or medical professional * score of \>14 on the Social Communication Questionnaire-Lifetime (SCQ-L) completed with the mother or father * meet DSM-5 criteria for ASD based on a Diagnostic and Statistical Manual of Mental Disorders (DSM-5) ASD symptom checklist * willing and motivated to participate in the treatment * a parent willing to participate * verbal intelligence quotient (IQ) score \>70 as assessed by the Kaufman Brief Intelligence Test 2nd edition revised (KBIT-2-R) Exclusion Criteria: * history of a psychotic disorder or current psychotic symptoms * suicidal ideation with intent or plan * current alcohol or other substance use disorder rated severe * concurrent enrollment in another clinical trial for autism spectrum disorder * expression of unwillingness to complete study procedures
Contact & Investigator
Antonio Pagan, PhD
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center, Houston
Frequently Asked Questions
Who can join the NCT06868537 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 25 Years, studying Autism Spectrum Disorder (ASD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06868537 currently recruiting?
Yes, NCT06868537 is actively recruiting participants. Contact the research team at Antonio.Pagan@uth.tmc.edu for enrollment information.
Where is the NCT06868537 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06868537 clinical trial?
NCT06868537 is sponsored by The University of Texas Health Science Center, Houston. The principal investigator is Antonio Pagan, PhD at The University of Texas Health Science Center, Houston. The trial plans to enroll 40 participants.